Home/Biosimilar Atlas/Companies/Juno Pharma Canada

Juno Pharma Canada

Biosimilar developer, Canada. 1 development product across 1 molecule: enoxaparin sodium.

First approval in the Atlas: Oct 2020, Noromby, enoxaparin sodium (HC)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Enoxaparin sodiumNoromby····Oct 2020··1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Juno Pharma Canada, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

BaxterOne shared molecule: enoxaparin sodium2 molecules in its portfolioFresenius KabiOne shared molecule: enoxaparin sodium5 molecules in its portfolioPharmathenOne shared molecule: enoxaparin sodium1 molecule in its portfolioSandozOne shared molecule: enoxaparin sodium10 molecules in its portfolioTechdowOne shared molecule: enoxaparin sodium1 molecule in its portfolio

Chronology

Compare Juno Pharma Canada with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.